Acceptance rate


Time to first decision

6 days*

Time to first decision with review

59 days*

Acceptance to publication

15 days*

Impact Factor (JCR)




Aims and scope

European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.

With peer reviewed papers, features, conference reports and more on topics covering all aspects of hospital pharmacy from both a scientific and practice perspective, the journal aims to highlight innovations and developments in pharmaceutical and biomedical sciences, promoting safe, efficacious and cost-effective pharmaceutical care for hospital pharmacists to practise.

For information about the European Journal of Hospital Pharmacy Editor-in-Chief Prof Phil Wiffen and his editorial team, please refer to the Editorial Board page.

Plan S compliance

European Journal of Hospital Pharmacy is a Plan S compliant Transformative Journal. Transformative Journals are one of the compliance routes offered by cOAlition S funders, such as Wellcome, WHO and UKRI. Find out more about Transformative Journals and  Plan S compliance on our Author Hub.

Journal information

Ownership BMJ publishes EJHP on behalf of the European Association of Hospital Pharmacists.
Publication Model Subscription; with hybrid open access option
Frequency Bi-monthly
Launch date 2012
Digital Archives Portico, LOCKSS
Indexed by Web of Science Core Collection: Science Citation Index Expanded, Medline, PubMed Central, Scopus, Embase (Excerpta Medica), Google Scholar
Peer Review Model Single anonymised; the names of reviewers are hidden from the author
Print ISSN 2047-9956
Online ISSN 2047-9964

Journal Statistics (2021)

Acceptance rate: 32%

Time to first decision without review (median): 6 days
Time to first decision with review (median): 59 days
Time from acceptance to publication (median): 15 days

Impact Factor category: Pharmacology and Pharmacy
Impact Factor (JCR): 2.530
Impact Factor rank (JCR): 205/279
5 year Impact Factor: 2.091
Journal Citation Indicator (JCI): 0.4
Eigenfactor: 0.00137
Citescore: 2.3
Citescore rank: 12/36
Scimago Journal Rank (SJR): 0.392

2021 total content views: 110,565
2021 total Altmetric mentions: 607

The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.

How we get these metrics

Contact information

For all contact information please refer to the Contact us page.

For authors

Please refer to the Instructions for authors


To advertise

Rights and permissions


COPE logo

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.


The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

AllTrials logo

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.